1. Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.
- Author
-
Safa-Tahar-Henni S, Páez Martinez K, Gress V, Esparza N, Roques É, Bonnet-Magnaval F, Bilodeau M, Gagné V, Bresson E, Cardin S, El-Hachem N, Iasenza I, Alzial G, Boivin I, Nakamichi N, Soufflet AC, Mirela Pascariu C, Duchaine J, Mathien S, Bonneil É, Eppert K, Marinier A, Sauvageau G, Deblois G, Thibault P, Hébert J, Eaves CJ, Cellot S, Barabé F, and Wilhelm BT
- Abstract
Targeted therapeutics for high-risk cancers remain an unmet medical need. Here we report the results of a large-scale screen of over 11,000 molecules for their ability to inhibit the survival and growth in vitro of human leukemic cells from multiple sources including patient samples, de novo generated human leukemia models, and established human leukemic cell lines. The responses of cells from de novo models were most similar to those of patient samples, both of which showed striking differences from the cell-line responses. Analysis of differences in subtype-specific therapeutic vulnerabilities made possible by the scale of this screen enabled the identification of new specific modulators of apoptosis, while also highlighting the complex polypharmacology of anti-leukemic small molecules such as shikonin. These findings introduce a new platform for uncovering new therapeutic options for high-risk human leukemia, in addition to reinforcing the importance of the test sample choice for effective drug discovery., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF